key: cord-0893323-a98b4yhc
authors: Jagannathan, P.; Andrews, J.; Bonilla, H.; Hedlin, H.; Jacobson, K.; Balasubramanian, V.; Purington, N.; Kamble, S.; de Vries, C.; Quintero, O.; Feng, K.; Ley, C.; Winslow, D.; Newberry, J.; Edwards, K.; Hislop, C.; Choong, I.; Maldonado, Y.; Glenn, J.; Bhatt, A.; Blish, C.; Wang, T.; Khosla, C.; Pinsky, B.; Desai, M.; Parsonnet, J.; Singh, U.
title: Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
date: 2020-11-23
journal: nan
DOI: 10.1101/2020.11.18.20234161
sha: 08265427a9e63c5edda8870e742a5b68ba9e3401
doc_id: 893323
cord_uid: a98b4yhc

Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized placebo-controlled trial in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint, NCT04331899). In both the 60 patients receiving Lambda and the 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively (HR 0.94; 95% CI 0.64 to 1.39). At enrollment; 41% of subjects were SARS-CoV-2 IgG seropositive; compared to placebo, lambda tended to delay shedding cessation in seronegatives (aHR 0.66, 95% CI 0.39-1.10) and to hasten shedding cessation in seropositives (aHR 1.58, 95% CI 0.88-2.86; p for interaction = 0.03). Liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.

We enrolled 120 participants between April 25 and July 17, 2020, of whom 110 (91.7%) 92 completed 28 days of follow up (Fig 1a) . The median age was 36 years (range 18-71), 50 93 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint participants (41.7%) were female, and 75 (62.5%) were Latinx ethnicity ( Table 1) . Eight (6.7%) 94 participants were asymptomatic at baseline. Of those with symptoms, the median duration of 95 symptoms prior to randomization was five days. The most common symptoms were fatigue, 96 cough, headache, and myalgias (Table 1, Fig S1) . Only 13 (10.8%) participants had an elevated 97 temperature (>99.5°F) at baseline; the median oxygen saturation was 98%. 98

Baseline oropharyngeal viral RNA level and SARS-CoV-2 IgG serostatus 100

The presence of SARS-CoV-2 RNA was assessed at baseline and at 8 follow-up visits using 101 oropharyngeal swabs, a Centers for Disease Control approved method for SARS-CoV-2 102 detection 24 . This method was selected given the frequency of repeated assessments and improved 103 tolerability for participants compared with nasopharyngeal swabs. The median SARS-CoV-2 104 oropharyngeal viral PCR cycle threshold at enrollment was 30.3 (corresponding to a median viral 105 load of 4.4 Log10 copies/ml), and did not differ significantly between groups ( Table 1) . 106 107 IgG antibody titers against the SARS-CoV-2 spike receptor binding domain (RBD) were 108 assessed at enrollment by enzyme linked immunosorbent assay. 25 At enrollment, 49 (40.8%) 109 participants were SARS-CoV-2 IgG seropositive. Baseline SARS-CoV-2 serostatus did not 110 significantly differ between groups ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint 117 Primary Virologic Analysis 118

Of 120 enrolled participants, 60 were randomized to receive Lambda and 60 randomized to 119 receive placebo and included in the analysis. The median time to cessation of oropharyngeal 120 viral shedding was 7 days in both arms (95% CI 5-10 days for placebo vs 5-13 days for Lambda, 121 Table 2 ). There was no significant difference in the adjusted hazard ratio (aHR) for shedding 122 cessation between Lambda and placebo; participants in the lambda arm were 19% less likely to 123 cease shedding at any point during the study period compared to participants in the placebo arm 124 (aHR 0.81, 95% confidence interval [CI] 0.56 to 1.19; p = 0.29, Fig 2A. ) Overall, 108 125 participants met the primary endpoint and were not censored. Because two participants, after 126 randomization, inadvertently were injected with the incorrect syringe, we also conducted an as-127 treated analysis according to treatment actually received. Findings from an as-treated analysis 128 (aHR 0.83, 95% CI 0.56 to 1.21; p = 0.33) and an analysis performed in symptomatic patients 129 only (aHR 0.77, 95% CI 0.52 to 1.15, p = 0.21) were similar. 130

In exploratory analysis, seropositivity at baseline was associated with significantly hastened 132 shedding cessation. The median time to shedding cessation was 10 days in SARS-CoV-2 IgG 133 seronegative individuals vs. 3 days in seropositive individuals (95% CI 7-14 days for 134 seronegative vs 1-6 days for seropositive, aHR 2.65, 95% CI 1.74-4.03, P<0.001, Fig S2) . 135

Baseline serostatus also significantly modified the effect of treatment on time to shedding 136 cessation (p = 0.03). Among seronegative individuals, Lambda delayed shedding cessation 137 compared with placebo (aHR 0.66, 95% CI 0.39-1 .10, Fig 3a) . Among seropositive individuals, 138

Lambda hastened shedding cessation (aHR 1.58, 95% CI 0.88-2. 86, Fig 3a) . 139 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint

Higher oropharyngeal viral RNA levels at baseline were associated with significantly delayed 141 shedding cessation (aHR 0.32 comparing baseline CT <30 vs baseline CT >=30, 95% CI 0.21-142 0.50, P<0.001, Fig S3) . Although baseline oropharyngeal viral RNA levels did not significantly 143 modify the effect of treatment on time to shedding cessation (p=0.15), among individuals with 144 high baseline viral RNA levels, Lambda delayed shedding cessation compared with placebo 145 (aHR 0.51, 95% CI 0.26-1. 04, Fig 3b) . There was no difference in shedding cessation between 146 arms with low baseline viral RNA levels (aHR 0.95, 95% CI 0.60-1. 52, Fig 3b) Twenty-five (42%) Lambda and 21 (35%) placebo participants experienced adverse events 160 (Table 3) . Two serious adverse events (hospitalizations) were reported in each arm. Liver 161 transaminase elevations were more common in the Lambda vs. placebo arm (15 vs 5; p = 0.027). 162 Furthermore, we observed significant elevations in alanine transaminase levels from day 0 to day 163 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint 5 among individuals randomized to Lambda, but not among individuals randomized to placebo 164 (Fig 4) . However, there were no associated symptoms and lab abnormalities were not sustained. The lack of effect of Lambda was surprising given recently described in vitro data and benefits 180 seen in an in vivo model with early therapeutic and prophylactic administration 12 . There are 181 several potential reasons for this lack of benefit. First, although we attempted to randomize 182 participants as soon as possible after the COVID-19 diagnosis was made, the median symptom 183 duration was 5 days at the time of randomization, and 40% of participants were already SARS-184

CoV-2 IgG positive at enrollment. It is possible that earlier administration, or prophylactic 185 administration prior to established infection, would have been beneficial. Arguing against this, 186 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were also more likely to have neutralizing auto-antibodies against type I, but not type III, IFNs 31 . 208 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint These data suggest the possibility that type I IFN administration may be more beneficial than 209 type III IFN in preventing adverse outcomes of SARS-CoV-2 infection. 210

Although there was some evidence that SARS-CoV-2 seropositivity at baseline modified the 212 effect of treatment on shedding cessation, the effect modification was in the opposite direction 213 than we had anticipated; Lambda appeared to prolong shedding relative to placebo among those 214 who were seronegative at baseline, and to shorten the duration of shedding among those who 215 were seropositive at baseline. Furthermore, Lambda also appeared to prolong shedding relative 216 to placebo among those with high baseline viral RNA levels. These findings should be 217 interpreted with caution for two reasons. First, these were exploratory analysis only and should 218 be considered hypothesis generating. Second, these observations defy biological plausibility 219 based on in vitro and animal model data. The study did have a few limitations. We recruited both symptomatic and asymptomatic patients. 229

Asymptomatic patients contributed less to secondary outcomes since they presented with lower 230 viral RNA levels and could not contribute to analyses of symptom alleviation. However, these 231 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint patients represented <10% of the enrolled cohort. Additionally, despite a reported median 232 duration of symptoms prior to randomization of only 5 days, 40% of participants were already 233 seropositive at enrollment. Unpublished data from a Regeneron outpatient monoclonal antibody 234 study with similar study design (REGN-COV2) found similar rates of baseline SARS-CoV-2 235

IgG seropositivity (45%). 37 These data suggest that enrolling COVID-19 outpatients early in the 236 course of disease, before they develop an antibody response, may be challenging. Nonetheless, 237

we found no suggestion of benefit of Lambda in seronegative individuals. Finally, the median 238 time to cessation in the placebo arm was shorter than assumed in our sample size calculations, Methods 252

We conducted a Phase 2, single-blind, randomized placebo-controlled trial to evaluate the 254 efficacy of Lambda in reducing the duration of viral shedding in outpatients. The trial was 255 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were randomly assigned to Lambda or placebo using a 1:1 REDCAP-based computer-generated 276 randomization scheme that stratified by age (≥ 50 and < 50 years old) and sex. A password-277 protected electronic spreadsheet containing the randomization allocation, along with the code 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint used to generate the allocation and seed used in the random number generation, was stored on 279 secure servers at Stanford. 280 281

Phase 2 studies established the optimal dose for virologic suppression and minimizing treatment-283 related adverse events (mainly aminotransferase and/or bilirubin elevations) for hepatitis C at 284

Stanford Investigational Pharmacy). The study medication/placebo syringe was dispensed by the 289 Stanford Investigational Pharmacist and administered by a study nurse. Lambda and placebo 290 syringes were identically labeled but differed in the appearance of the needle hub. Since the 291 nurse administering the medication might see syringe differences, the study was not strictly 292 "double-blind" even though all participants and investigators were blinded to treatment arm. 293

Participants were monitored for adverse events for thirty minutes after injection. 294 295

Participants completed a daily symptom questionnaire using REDCap Cloud version 1.5. 297

Participants also provided in-home measurements of temperature and oxygen saturation using 298 study-provided devices. In-person follow-up visits were conducted at Day 1, 3, 5, 7, 10, 14, 21, 299 and 28, with assessment of symptoms and vitals, and collection of oropharyngeal swabs (FLOQ 300 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Analyses were performed according to assigned randomization arm (intent-to-treat). Absolute 344 standardized differences are displayed to compare the distribution of baseline characteristics 41 . 345

All models were covariate-adjusted for the randomization strata of age group and sex. Unless 346 otherwise noted, all tests were two-sided and conducted at the 0.05 level of significance. 347

Analyses were performed in R version 4.0.2. 42 348 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint 349 Primary analysis: Time until shedding cessation was compared between arms using a Cox 350 proportional hazards model covariate-adjusted for age and sex, with the final hypothesis test 351 conducted at the alpha = 0·04999 level of significance to allow for an interim analysis. The 352 hazard ratio for shedding cessation was estimated, along with its 95% confidence interval. Estimates for change in viral load and viral load AUC for lambda compared to placebo and 369 corresponding 95% confidence intervals for the linear models were reported. The incidence of 370 hospitalizations and emergency department visits was estimated for each arm, with 95% 371 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 23, 2020. Post hoc analyses were conducted to test for differences in both median duration of symptoms 391 pre-randomization and baseline log 10 viral load between seronegative and seropositive 392 participants. The Kruskal-Wallis rank sum was used to test for differences in symptom duration 393 while a two-sample t-test was used to test for differences in log 10 viral load. 394 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint

Assuming 1:1 randomization and the use of a two-sided log rank test at the alpha=0.04999 level 396 of significance for the final analysis, we anticipated the occurrence of 79 shedding cessation 397 events, which provided 80% power to detect a hazard ratio of 2.03. We additionally assumed 398 median time to shedding cessation of 14 days in the control arm and 7 days in the treatment arm, 399 a two-month accrual period, a two-week follow-up period after randomization of the last patient, 400 and 10% drop out in the control arm. This enabled an interim analysis conducted at 401 alpha=0·00001 to assess overwhelming efficacy after 50% of participants completed 24 hours of 402 follow-up. We estimated that the total sample size required to achieve 79 events was 120 (60 403 participants per arm). Acknowledgements 417 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint

We thank all study participants who participated in this study, and the study team for their 418 tireless work. We also thank our colleagues at Stanford University Occupational Health and at . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint 

Duration until viral shedding cessation in days, median (95% CI) 7 (5-13) 7 (5-10)

Duration until resolution of symptoms in days, median (95% CI) 8 (6-11) 9 (5-11) Hospitalizations by Day 28, n participants (%) 2 (3.3%) 2 (3.3%) Emergency Department visits by Day 28, n participants (%) 5 (8.3%) 3 (5%)

Log Oropharyngeal viral load over time, mean change at day 14 (SD) -4.3 (4.3) -4.9 (4.7)

Log 10 viral load area under the curve through day 14, median (IQR) 28.5 (20.1) 29.6 (19.0)

Duration until sustained symptom resolution in days, median (95% CI) 20 (16-27) 20 (17-24) Duration until respiratory symptom resolution in days, median (95% CI) 6 (4-7) 4 (2-7) Duration until systemic and respiratory symptom resolution in days, median (95% CI) 8 (6-11) 5.5 (5-10) Duration until disease progression in days, median among those who progress* (IQR) 5 (1) 2 (1) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint 600 601 602 603 604 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.18.20234161 doi: medRxiv preprint

COVID-19 Dashboard by the Center for Systems Science and Engineering

Real estimates of mortality following COVID-19 infection

Type I and Type III Interferons -Induction, Signaling, Evasion, 453 and Application to Combat COVID-19

Type III interferon (IFN) induces a type I IFN-like response in a restricted 456 subset of cells through signaling pathways involving both the Jak-STAT pathway and the 457 mitogen-activated protein kinases

Shared and Distinct Functions of Type 459 I and Type III Interferons

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent 461 interferon antagonists

Comparative replication and immune activation profiles of SARS-CoV-2 463 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis 464 of COVID-19

Systems biological assessment of immunity to mild versus 466 severe COVID-19 infection in humans

Impaired type I interferon activity and inflammatory responses in 468 severe COVID-19 patients

Inhibition of SARS-CoV-2 by type I and type III interferons

A mouse-adapted model of SARS-CoV-2 to test COVID-19 472 countermeasures

Interferon-alpha2b Treatment for COVID-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and 476 ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, 477 randomised, phase 2 trial

COVID-19 -SG016 Clinical Trial Data Readout

Lambda interferon renders epithelial cells of the respiratory and 480 gastrointestinal tracts resistant to viral infections

IFN-lambda (IFN-lambda) is 482 expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

Lambda and 485 alpha interferons inhibit hepatitis B virus replication through a common molecular 486 mechanism but with different in vivo activities

Lambda interferon inhibits hepatitis B and C 488 virus replication

IFNlambda is a potent anti-influenza therapeutic without the 490 inflammatory side effects of IFNalpha treatment